Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 141

Results For "RMAT"

1996 News Found

Football sized rare mesenteric tumour removed laparoscopically at the CK Birla Hospital
News | September 07, 2022

Football sized rare mesenteric tumour removed laparoscopically at the CK Birla Hospital

In a rare occurrence worldwide, the CK Birla Hospital® treats 32-year-old woman for a giant mesenteric tumour via complex laparoscopic surgery


Mandaviya virtually lays Foundation Stone of NCDC branches in 6 states
Policy | September 07, 2022

Mandaviya virtually lays Foundation Stone of NCDC branches in 6 states

NCDC branches in States/UTs will provide a boost to Public Health Infrastructurewith prompt surveillance, rapid detection and timely monitoring of diseases enabling Early Interventions


Ginkgo Bioworks appoints Dr. Behzad Mahdavi as Sr. VP of Biopharma Manufacturing & Life Science Tools
People | September 03, 2022

Ginkgo Bioworks appoints Dr. Behzad Mahdavi as Sr. VP of Biopharma Manufacturing & Life Science Tools

Dr. Mahdavi will lead Ginkgo's commercial efforts in the growing areas of bio-reagents, cell and gene therapies and new biopharmaceutical modalities.


USFDA approves first treatment option for generalized pustular psoriasis flares in adults
Drug Approval | September 03, 2022

USFDA approves first treatment option for generalized pustular psoriasis flares in adults

Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares


Stelis Biopharma’s flagship facility receives EIR from USFDA
Drug Approval | September 01, 2022

Stelis Biopharma’s flagship facility receives EIR from USFDA

The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise


Bayer initiates Phase III study program to investigate oral FXIa inhibitor asundexian
Clinical Trials | September 01, 2022

Bayer initiates Phase III study program to investigate oral FXIa inhibitor asundexian

The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke


Hydration of proteins could act as a potential marker for an early detection of neuro-degenerative diseases
News | September 01, 2022

Hydration of proteins could act as a potential marker for an early detection of neuro-degenerative diseases

This dense phase often resembles liquid droplets exhibiting higher protein density and weaker molecular motion than the surrounding medium.


Medix Biochemica appoints former Roche executive to its Board of Directors
People | September 01, 2022

Medix Biochemica appoints former Roche executive to its Board of Directors

Dr. Pedrocchi is currently an Independent Strategic Advisor and Non-Executive Director to private and public healthcare companies.


Merck India inaugurates R&D Excellence Centre in Bangalore
News | September 01, 2022

Merck India inaugurates R&D Excellence Centre in Bangalore

The Centre aims at promoting innovation among the scientific community to improve healthcare solutions around the globe


Moderna sues Pfizer, BioNTech for mRNA patent infringement
News | August 28, 2022

Moderna sues Pfizer, BioNTech for mRNA patent infringement

Complaints to be filed in both United States and Germany alleging that Pfizer and BioNTech's COVID-19 vaccine Comirnaty unlawfully infringes patents Moderna filed between 2010 and 2016